乙基胺酸合成酶基因的多态性和急性淋巴细胞白血病的结果
M Krajinovic1, I Costea, S Chiasson
1Service d'Hématologie-Oncologie, Centre de Recherche, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine, Quebec H3T 1C5, Montreal, Canada. maja.krajinovic@umontreal.ca
Lancet (London, England)
|April 9, 2002
概括
一种胺基酸合成酶基因多态性与急性淋巴细胞白血病的儿童接受甲醇治疗的结果较差有关. 基因定型可能允许个性化治疗策略.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 药物基因组学 药物基因组学
背景情况:
- 在癌症治疗中,甲状腺素对甲状腺素反应的个体间变异是令人担忧的.
- 甲基基酸合成酶 (TS) 酶度是甲基酸盐疗效的关键决定因素.
- 在TS促进区的特定多态可能会影响TS表达水平.
研究的目的:
- 为了研究TS促进体和小儿急性淋巴细胞白血病 (ALL) 治疗结果之间的协同重复多态关系.
- 为了确定这种遗传变异是否会影响以甲醇基化疗的有效性.
主要方法:
- 从205名被诊断患有ALL的儿童收集了DNA样本.
- 用聚合酶链反应 (PCR) 试验来分析TS促进体多态性.
- 基因型与临床结果相关,包括治疗反应和预后.
主要成果:
- 在TS促销者中对三重重复基因型具有同卵性儿童的前景明显较差.
- 概率比率为4.1 (95%CI为1.9-9.0,p=0.001) 表示与这种基因型相关的风险增加.
- 这表明,三重重复基因型与治疗效率降低或疾病攻击性增加有关.
结论:
- 鉴定到的TS促进体多态性与儿科ALL患者用甲醇治疗的不良结果有关.
- 对这种TS多态的基因定型可以帮助识别风险较高的患者.
- 基于TS基因型的个性化治疗策略可能会改善急性淋巴细胞白血病的治疗结果.
相关概念视频
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...